ArticleScience advances2019
Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke.
Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Research trends and topics on sepsis immunosuppression: a bibliometric and visual analysis of global research from 2004 to 2024.Frontiers in medicine · 2025Pooled it
- Nanodrugs for the Treatment of Ischemic Stroke: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm.Biomaterials · 2021Trial
- Cell-inspired dual-tandem catalytic nanoreactors drive targeted hearing protection.Nature communications · 2026Article
- Artificial exosomes synergistically reshape sepsis immune homeostasis by modulating neutrophil fate and blocking PD-1/PD-L1.Cell reports. Medicine · 2026Article
- Immunomodulatory Nanomaterials: Design Strategies, Mechanisms, Biomedical Applications, and Future Perspectives.Biomedicines · 2026Review
- Harnessing Targeted Polymerized Salicylic Acid Particles to Mitigate Neutrophil-Driven Inflammation.ACS biomaterials science & engineering · 2026Article
- Albumin Nanoparticles Harness Activated Neutrophils to Cross Vascular Barriers for Targeted Subcutaneous and Orthotopic Colon Cancer Therapy.Journal of functional biomaterials · 2026Article
- Decoy Nanoparticles and Protein Corona Modulation: A Novel Frontier in Sepsis Treatment.International journal of nanomedicine · 2026Review
- Emerging Nanomedicine Strategies for Sepsis: Immunomodulation and Beyond.Research (Washington, D.C.) · 2026Article
- Targeting a specific subset of neutrophils to mitigate cardiac reperfusion injury.Research square · 2025Article
- Nanoplatforms in sepsis storm: Multimodal synergy for precision immunomodulation and pathogen neutralizations.Pharmaceutical science advances · 2025Review
- Harnessing biomaterials for tuning inflammation: A neutrophil-centric perspective.Materials today. Bio · 2025Review
- Advanced nanotherapies for precision treatment of inflammatory lung diseases.Bioactive materials · 2025Review
- Advanced Nanoparticle Therapeutics for Targeting Neutrophils in Inflammatory Diseases.Advanced healthcare materials · 2025Review
- Harnessing smart nanomaterials to reprogram neutrophil plasticity in immune modulation.Journal of nanobiotechnology · 2025Review
- Neutrophils loaded NADMaterials today. Bio · 2025Article
- Cell death signaling and immune regulation: new perspectives on targeted therapy for sepsis.Cellular & molecular biology letters · 2025Review
- Unraveling immunosenescence in sepsis: from cellular mechanisms to therapeutics.Cell death & disease · 2025Review
- The impact of aging on neutrophil functions and the contribution to periodontitis.International journal of oral science · 2025Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Human neutrophils are the most abundant circulating leukocytes and contribute to acute and chronic inflammatory disorders. Neutrophil apoptosis is programed cell death to maintain immune homeostasis, but inflammatory responses to infections or tissue injury disrupt neutrophil death program, leading to many diseases. Precise control of neutrophil apoptosis may resolve inflammation to return immune homeostasis. Here, we report a method in which doxorubicin (DOX)-conjugated protein nanoparticles (NPs) can in situ selectively target inflammatory neutrophils for intracellular delivery of DOX that induces neutrophil apoptosis. We showed that neutrophil uptake of NPs required their activation and was highly selective. DOX release was triggered by acidic environments in neutrophils, subsequently inhibiting neutrophil transmigration and inflammatory responses. In two disease models, DOX-conjugated NPs notably increased mouse survival in sepsis and prevented brain damage in cerebral ischemia/reperfusion, but the NPs did not suppress systemic immunity. Our studies offer a promising strategy to treat inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.